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suitability for use as a biomarker in DMOAD development. If suc- 
cessful, these methods could both accelerate the early evalua- 
tion of new molecules and demonstrate preservation on cartilage 
composition to support regulatory submission for licensure. 
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SERUM AND URINE BIOCHEMICAL MARKERS FOR USE 
IN OSTEOARTHRITIS CLINICAL TRIALS 
Joanne M Jordan 
Using radiographic outcomes, clinical trials of potential disease 
modifying interventions for development and progression of os- 
teoarthritis, typically last 2 to 3 years. Such trials are expensive, 
difficult o perform, and subject to biases from attrition and other 
methodologic problems. Inability to accurately identify individu- 
als likely to progress, for selection into a disease-modification 
trial, can limit statistical power if insufficient numbers of individ- 
uals develop the outcome under study. More sensitive imaging 
measures of OA outcome, such as magnetic resonance imaging, 
have been discussed. Biochemical markers, measured in serum 
or urine, are also under investigation to substitute for radiographic 
or other OA outcomes that might require a longer trial duration, 
and to help identify individuals whose OA is likely to develop or 
progress quickly. If a biomarker or panel of biomarkers, in con- 
junction with clinical or other easily obtainable measures, were 
able to identify individuals at high risk of rapid OA progression or 
were to predict response to intervention early, then the duration, 
number of study participants, and expense of clinical trials could 
be decreased and efficiency enhanced. 
In 2003, the NIH/NIAMS established The Osteoarthritis Biomark- 
ers Network as an international consortium of five sites engaged 
in innovative approaches to biomarker development and testing 
in OA. This consortium is working to develop a classification 
scheme for OA biomarkers that could provide a consistent ter- 
minology and framework to facilitate research, development, and 
validation of biomarkers. This classification scheme, still under 
development, proposes five categories of markers: 1)Investiga- 
tive; 2) Diagnostic; 3) Burden of disease, encompassing mea- 
sures of disease activity and damage; 4) Prognostic, and 5) Effi- 
cacy (and toxicity) of intervention. These classification categories 
are not mutually exclusive, nor do they necessarily imply that a 
marker must move serially through each of the categories in its 
development. Markers can fulfill criteria in more than one cate- 
gory. This proposed classification scheme, criteria for the cate- 
gories, and examples of current serum and urine biomarkers in 
each category will be discussed. 
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GRADING SYSTEM FOR MOUSE OSTEOARTHRITIS 
Qian Chen, Sonya S Glasson 
In recent years, knockout and transgenic mouse has become a 
widely used model to determine the contribution of a specific 
gene to the development of a disease in viva. Many genes have 
been implicated in the pathogenesis of osteoarthritis (OA). How- 
ever, unlike the OA occurring in human joint cartilage, there is 
no standardized grading system to evaluate the progress of OA 
in mouse joint cartilage. The lack of a uniform mouse OA grading 
system has made comparison of different mouse OA models diffi- 
cult. The goal of this session is to gather the researchers who are 
working in the mouse OA field, and develop a mouse OA grading 
standard that is accepted by the research community. Such stan- 
dardized mouse OA grading system will become a guideline to 
assess the severity of OA in mouse joint cartilage. This session 
will consist of three parts. 
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IDENTIFICATION OF TARGETS THROUGH HISTOLOGIC 
EVALUATION OF OSTEOARTHRITIS IN KNOCK OUT 
MICE 
Sonya Glasson 
Introduction: There are no disease-modifying osteoarthritis 
drugs (DMOADs) currently available for the treatment of OA. In 
order to identify which enzymes or cytokines are important in 
viva, studies were performed in knock out (KO) mice that were 
challenged in a surgical instability model. Those KOs showing a 
decrease in OA severity, following histologic evaluation would be 
targets for the development of selective inhibitors. 
Methods: In an IACUC-approved protocol, 12 different 10- 
week old knock-out (KO) and strain-specific wild-type (WT) mice 
had surgical instability induced in their right knees via desta- 
bilization of the medial meniscus (DMM). IL-11~ (B10.RIII WT), 
MMP-3 (B10.RIII WT), COX-l, COX-2 (B6;129) KOs were from 
Taconic. Jak-3 (C57BL6) and MMP-9 KO (FVB/N WT) mice were 
from Jackson Laboratories (Bar Harbor, ME). MMP-12, cPLA2~ 
(C57BL/6 WT), MK2 (DBA), ADAMTS-4, -5, 4/5 (129SvEv WT) 
KO mice were from Wyeth. Ten males per experimental group 
were sacrificed 8 weeks post-operatively. Knees were fixed in 
4% paraformaldehyde, decalcified, stained with Safranin-O and 
scored by 2 blinded observers using a modified semi-quantitative 
system (Chambers et al. 1997) where a higher score reflects 
greater OA severity. Histologic scores were obtained from all four 
quadrants of the joint (MFC, MTP, LFC, LTP)across 12-16 levels 
spaced at 80 i~m intervals. Results were expressed as a sum of 
all scores and could also be expressed as maximal scores across 
the entire joint or within a specific location (MTP). 
Results: Severity of OA varied greatly depending on the WT 
strain, with the most severe OA in the 129/SvEv strain, fol- 
lowed by C57B10.RIII, C57BL/6, FVB/N and DBA. There were 
no differences between MMP-3, COX-l, COX-2, Jak-3, MMP-12, 
cPLA20~, or ADAMTS-4 KO mice and their respective wild-type 
controls. The MMP-9 and MK2 KO mice had higher scores, re- 
flecting more severe OA, than their WT controls. The scores in 
the IL-11~, ADAMTS-5 and ADAMTS-4/5 KOs were significantly 
decreased compared to controls, using any variation of the scor- 
ing scheme, although greater sensitivity was observed using the 
summed method. 
Discussion: Histologic evaluation of mouse knee joints following 
surgical instability is sensitive to the effects of strain and to dis- 
ease modification from IL-11~ or ADAMTS-5 deletion. More severe 
OA could be observed in MMP-9 or MK2 deficient mice, suggest- 
ing that these enzymes could play a protective role, or that other 
enzymes are up-regulated to compensate. The deletion of the 
majority of genes examined showed no impact on the progres- 
sion of OA, suggesting that these have an insignificant role in OA 
progression. 
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DESIGN AND CONDUCT OF CLINICAL TRIALS IN 
OSTEOARTHRITIS 
Marc C Hochberg 
The Osteoarthritis Research Society International has published 
recommendations for the conduct of clinical trials in patients with 
hip or knee osteoarthritis (1) and is developing similar recommen- 
dations for patients with hand osteoarthritis. This session will re- 
view the design of randomized clinical trials focusing on 1) types 
of trials (superiority, equivalence, non-inferiority), 2) types of con- 
trols (placebo, active treatment), 3) inclusion criteria (including 
use of American College of Rheumatology [ACR] classification 
criteria for case definition), 4) exclusion criteria, 5) types of in- 
